EVALUATION OF VACCINATION RESPONSE IN CHILDREN AFTER TREATMENT FOR ACUTE LEUKEMIA

Objective: Our study aims to evaluate the patients’ immunity regarding childhood vaccination after leukemia treatment and determine the vaccines that require additional doses. Methodology: Sixty-six patients who were followed up with the diagnosis of ALL and AML between 2013 and 2016 were included i...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Elif KILIC KONTE, Ayca KOCA YOZGAT, Aysun KARA UZUN, Hüsniye Nese YARALI, Bahar CUHACI CAKIR
Formato:	article
Lenguaje:	EN
Publicado:	Elsevier 2021
Materias:	Diseases of the blood and blood-forming organs RC633-647.5
Acceso en línea:	https://doaj.org/article/3d03d05361d845b48215b362c9fd9d56
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:3d03d05361d845b48215b362c9fd9d56
record_format	dspace
spelling	oai:doaj.org-article:3d03d05361d845b48215b362c9fd9d562021-11-10T04:38:41ZEVALUATION OF VACCINATION RESPONSE IN CHILDREN AFTER TREATMENT FOR ACUTE LEUKEMIA2531-137910.1016/j.htct.2021.10.1083https://doaj.org/article/3d03d05361d845b48215b362c9fd9d562021-11-01T00:00:00Zhttp://www.sciencedirect.com/science/article/pii/S253113792101230Xhttps://doaj.org/toc/2531-1379Objective: Our study aims to evaluate the patients’ immunity regarding childhood vaccination after leukemia treatment and determine the vaccines that require additional doses. Methodology: Sixty-six patients who were followed up with the diagnosis of ALL and AML between 2013 and 2016 were included in our study. The patient's gender, age at diagnosis, leukemia type, leukemia risk groups, vaccination status before chemotherapy (CT) and serologies of hepatitis A, hepatitis B, varicella, measles, rubella, mumps at the end of CT were recorded. Results: At the end of the treatment, loss of protective antibody response against hepatitis A (47.4%), hepatitis B (68.2%), varicella (64.2%), measles (45.5%), rubella (43.9%), and mumps (50%) vaccines were shown. Loss of protective antibodies against hepatitis A (66.7%), hepatitis B (100%), varicella (100%), measles (100%), rubella (91.7%), and mumps (91.7%) in high-risk ALL patients was higher than patients in standard-intermediate risk ALL. Conclusion: Loss of humoral immunity against hepatitis A, hepatitis B, varicella, MMR was shown in patients with leukemia at the end of the treatment. Due to the significant decrease in hepatitis B and MMR protective antibodies in the high-risk group, we recommend patients with leukemia who have completed chemotherapy to be vaccinated with hepatitis B vaccine three months and MMR vaccine six months after the treatment.Elif KILIC KONTEAyca KOCA YOZGATAysun KARA UZUNHüsniye Nese YARALIBahar CUHACI CAKIRElsevierarticleDiseases of the blood and blood-forming organsRC633-647.5ENHematology, Transfusion and Cell Therapy, Vol 43, Iss , Pp S60- (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Diseases of the blood and blood-forming organs RC633-647.5
spellingShingle	Diseases of the blood and blood-forming organs RC633-647.5 Elif KILIC KONTE Ayca KOCA YOZGAT Aysun KARA UZUN Hüsniye Nese YARALI Bahar CUHACI CAKIR EVALUATION OF VACCINATION RESPONSE IN CHILDREN AFTER TREATMENT FOR ACUTE LEUKEMIA
description	Objective: Our study aims to evaluate the patients’ immunity regarding childhood vaccination after leukemia treatment and determine the vaccines that require additional doses. Methodology: Sixty-six patients who were followed up with the diagnosis of ALL and AML between 2013 and 2016 were included in our study. The patient's gender, age at diagnosis, leukemia type, leukemia risk groups, vaccination status before chemotherapy (CT) and serologies of hepatitis A, hepatitis B, varicella, measles, rubella, mumps at the end of CT were recorded. Results: At the end of the treatment, loss of protective antibody response against hepatitis A (47.4%), hepatitis B (68.2%), varicella (64.2%), measles (45.5%), rubella (43.9%), and mumps (50%) vaccines were shown. Loss of protective antibodies against hepatitis A (66.7%), hepatitis B (100%), varicella (100%), measles (100%), rubella (91.7%), and mumps (91.7%) in high-risk ALL patients was higher than patients in standard-intermediate risk ALL. Conclusion: Loss of humoral immunity against hepatitis A, hepatitis B, varicella, MMR was shown in patients with leukemia at the end of the treatment. Due to the significant decrease in hepatitis B and MMR protective antibodies in the high-risk group, we recommend patients with leukemia who have completed chemotherapy to be vaccinated with hepatitis B vaccine three months and MMR vaccine six months after the treatment.
format	article
author	Elif KILIC KONTE Ayca KOCA YOZGAT Aysun KARA UZUN Hüsniye Nese YARALI Bahar CUHACI CAKIR
author_facet	Elif KILIC KONTE Ayca KOCA YOZGAT Aysun KARA UZUN Hüsniye Nese YARALI Bahar CUHACI CAKIR
author_sort	Elif KILIC KONTE
title	EVALUATION OF VACCINATION RESPONSE IN CHILDREN AFTER TREATMENT FOR ACUTE LEUKEMIA
title_short	EVALUATION OF VACCINATION RESPONSE IN CHILDREN AFTER TREATMENT FOR ACUTE LEUKEMIA
title_full	EVALUATION OF VACCINATION RESPONSE IN CHILDREN AFTER TREATMENT FOR ACUTE LEUKEMIA
title_fullStr	EVALUATION OF VACCINATION RESPONSE IN CHILDREN AFTER TREATMENT FOR ACUTE LEUKEMIA
title_full_unstemmed	EVALUATION OF VACCINATION RESPONSE IN CHILDREN AFTER TREATMENT FOR ACUTE LEUKEMIA
title_sort	evaluation of vaccination response in children after treatment for acute leukemia
publisher	Elsevier
publishDate	2021
url	https://doaj.org/article/3d03d05361d845b48215b362c9fd9d56
work_keys_str_mv	AT elifkilickonte evaluationofvaccinationresponseinchildrenaftertreatmentforacuteleukemia AT aycakocayozgat evaluationofvaccinationresponseinchildrenaftertreatmentforacuteleukemia AT aysunkarauzun evaluationofvaccinationresponseinchildrenaftertreatmentforacuteleukemia AT husniyeneseyarali evaluationofvaccinationresponseinchildrenaftertreatmentforacuteleukemia AT baharcuhacicakir evaluationofvaccinationresponseinchildrenaftertreatmentforacuteleukemia
_version_	1718440545353728000

EVALUATION OF VACCINATION RESPONSE IN CHILDREN AFTER TREATMENT FOR ACUTE LEUKEMIA

Ejemplares similares